Biosimilars

Rapid Biosimilar Adoption Possible in Community Oncology Practice

By Charlie Dawson

Biosimilars, ASCO 2021 Highlights

Biosimilars have the potential to create a more sustainable healthcare environment by offering substantial cost-savings and expanding patient access to lifesaving therapies. At the ASCO 2021 virtual annual meeting, Lalan S. Wilfong, MD, Executive Vice President, Value-Based Care and Quality Programs, and Medical Oncologist/Hematologist, Texas Oncology, Presbyterian Cancer Center Dallas, TX, discussed how a community practice model for therapeutic interchange of brand drugs to biosimilars led to a significant increase in utilization of biosimilars and substantial cost-savings over the course of a single year at his institution. Read More ›

ASCO Publishes First Guideline on Use of Molecular Biomarkers in Localized Prostate Cancer

By Rebecca Bailey

The clinical course of prostate cancer is highly variable, reflecting the heterogeneity of the disease. Although most men diagnosed with prostate cancer have low-risk, favorable disease characteristics, some may harbor aggressive features and experience disease progression despite conventional therapy. Read More ›

FDA Commissioner Urges Insurers to Support Biosimilar Competition

FDA Commissioner Urges Insurers to Support Biosimilar Competition

By Sophie Granger

Although the FDA does not have a hand in the regulation of drug prices, the safeguarding of access to medications is a crucial factor in the agency’s goal to foster and protect public health.

FDA Provides Further Guidance on Biosimilars and Biologics

By Sophie Granger

According to the ACR, a practical benefit of the guidance is that in situations where a biosimilar is not considered interchangeable, a pharmacist must ask the prescribing physician for a new prescription before switching a patient to or from a reference biologic.

Understanding Risks and Benefits: A Biosimilar Primer

Bellevue, WA—Although biologics have been a potent addition to the rheumatologist’s armamentarium, they come with complications, too, including high costs and regulatory confusion. In other words, their complexity extends far beyond the manufacturing process. Read More ›

Cautious Stance Taken by American College of Rheumatology’s Position Statement on Biosimilars

By Rosemary Frei, MSc

The American College of Rheumatology (ACR) has released an official position statement on biosimilars, on the heels of the first biosimilar approval by the US Food and Drug Administration (FDA). Filgrastim-sndz (Zarxio, Sandoz) was approved on March 6, 2015. Read More ›

Biosimilar Infliximab Entering Use in 12 European Countries

By Caroline Helwick

European physicians across 12 countries now have access to a more cost-effective treatment for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory conditions, with the approval of the first biosimilar monoclonal antibody for infliximab, CT-P13 (Remsima, Celltrion; Inflectra, Hospira), by the European Medicines Agency (EMA). Read More ›

Subscribe to Urology Practice Management

Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or e‑Newsletters.

Select the lists you wish to subscribe to*

UPM e-Newsletter

UPM print publication

First Name*

Last Name*

Email*

Country*

Address

Address (Continued)

City

State / Province

ZIP Code

Please verify your request*